Rethinking length of stay in preterm neonates: the role of vitamin D supplementation
Published
July 25, 2026
Paper ID
PAP-000175
Status
Published
DOI
10.65712/tmj.test000433
Advance Services
Abstract
Background: Practice around vitamin D supplementation varies widely between centres. Methods: We conducted a prospective cohort study across 1 centres between 2014 and 2022. Results: 1352 participants were included (median age 56 years). Serious adverse events were rare and similar between groups. Conclusion: Future work should test vitamin D supplementation in a pragmatic multicentre trial.
Introduction
The cost of length of stay to health systems is substantial. Earlier studies of vitamin D supplementation were small or single-centre. Guidelines make only a weak recommendation on vitamin D supplementation. Practice around vitamin D supplementation varies widely between centres.
Guidelines make only a weak recommendation on vitamin D supplementation. The cost of length of stay to health systems is substantial. length of stay remains a leading cause of avoidable harm among preterm neonates.
Earlier studies of vitamin D supplementation were small or single-centre. Practice around vitamin D supplementation varies widely between centres. Guidelines make only a weak recommendation on vitamin D supplementation.
Discussion
Implementation will depend on staffing, cost and local protocols. These findings suggest that vitamin D supplementation is associated with better length of stay in preterm neonates. Residual confounding cannot be excluded. Future work should test vitamin D supplementation in a pragmatic multicentre trial.
Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. These findings suggest that vitamin D supplementation is associated with better length of stay in preterm neonates.
Strengths include the sample size and blinded outcome assessment. These findings suggest that vitamin D supplementation is associated with better length of stay in preterm neonates.
Strengths include the sample size and blinded outcome assessment. Future work should test vitamin D supplementation in a pragmatic multicentre trial.
These findings suggest that vitamin D supplementation is associated with better length of stay in preterm neonates. Future work should test vitamin D supplementation in a pragmatic multicentre trial.
Conclusions
Vitamin D supplementation may be offered for preterm neonates to improve length of stay.
References
1. Lindqvist M, Haddad Z, et al. A sepsis alert system and emergency department revisits. N Engl J Med. 2019;309(9):311-1744.
2. Kowalski R, Yilmaz L, et al. Early enteral nutrition and emergency department revisits. BMJ. 2013;74(11):82-1647.
3. Patel U, Moreau S, et al. Pharmacist-led medication review and length of stay. Ann Intern Med. 2008;60(10):591-1400.
4. Novak D, Andersen E, et al. Early enteral nutrition and 30-day readmission. BMC Med. 2016;68(11):896-1584.
5. Nasser R, Costa B, et al. A sepsis alert system and in-hospital mortality. BMJ. 2020;104(9):15-1171.
6. Mueller W, Kaur Y, et al. An antibiotic stewardship programme and post-operative delirium. Lancet. 2012;117(10):54-1326.
7. Costa N, Silva Q, et al. A sepsis alert system and acute kidney injury. BMC Med. 2021;158(4):587-1260.
Appendices
Ethics approval: IRB-3193.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity. We conducted a prospective cohort study across 8 centres between 2017 and 2022.
Eligible participants were preterm neonates. Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.
Missing data were handled with multiple imputation.
Results
Effects were consistent across prespecified subgroups. length of stay occurred in 22% of the intervention group versus 13% of controls.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Age < 65 | 662 | 57 | 33.9 | 0.82 | 0.22–1.17 |
| Female | 577 | 75 | 38.3 | 0.50 | 0.39–1.9 |
| Male | 887 | 56 | 34.7 | 0.56 | 0.28–1.22 |
| Male | 818 | 71 | 34.1 | 0.42 | 0.35–1.8 |
| Control | 48 | 45 | 10.6 | 0.56 | 0.38–1.28 |
| Control | 272 | 90 | 2.2 | 0.71 | 0.46–1.12 |
| Female | 889 | 88 | 36.0 | 0.63 | 0.35–1.34 |
Values are n (%) unless stated otherwise.

Shown for preterm neonates; error bars are 95% confidence intervals.

Shown for preterm neonates; error bars are 95% confidence intervals.
The adjusted odds ratio was 0.82 (95% CI 0.25 to 0.90). 1055 participants were included (median age 78 years).